Remote care solutions provider Sentrian has announced that it’s embarking on a major study on the benefits of its technology. The company has teamed up with the Scripps Translational Science Institute (STSI) and the CareMore Health System to set up a study involving a thousand patients suffering from chronic obstructive pulmonary disease (COPD).
The main goal of the year-long study is to see if Sentrian’s Remote Patient Intelligence (RPI) platform can detect the onset of a patient’s acute event, and to see how accurately it’s able to do so. Positive findings would validate the RPI platform as a major tool in the battle to fight COPD; according to Sentrian, almost 13 million Americans suffer from COPD, and one in 11 such patients need to be readmitted to hospital within 30 days of being discharged. And the company says its platform could prove useful in the management of other diseases, as well.
In a statement announcing the new study, Sentrian CEO Dean Sawyer emphasized the manifold benefits that could arise from the study and the promotion of the RPI platform. “By working with scientific and health care leaders like Scripps and CareMore,” he said, “I believe we can significantly reduce hospitalization and move toward the triple aim of health care – to simultaneously reduce cost, improve outcomes and improve patient satisfaction.”
While the findings of the study remain to be seen, there is good reason to be optimistic, given that Sentrian was recently recognized with the 2015 President’s Award for Innovation in Remote Health Care by the American Telemedecine Association.